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Abstract
Chemokines play a crucial role in inflammation and in the pathophysiology of atherosclerosis by recruiting inflammatory
immune cells to the endothelium. Chemokine CCL5 has been shown to be involved in atherosclerosis progression. However,
little is known about how CCL5 is regulated in vascular smooth muscle cells. In this study we report that CCL5 mRNA
expression was induced and peaked in aorta at day 7 and then declined after balloon artery injury, whereas IP-10 and MCP-1
mRNA expression were induced and peaked at day 3 and then rapidly declined. The expression of CCL5 receptors (CCR1, 3
& 5) were also rapidly induced and then declined except CCR5 which expression was still relatively high at day 14 after
balloon injury. In rat smooth muscle cells (SMCs), similar as in aorta CCL5 mRNA expression was induced and kept increasing
after LPS plus IFN-gamma stimulation, whereas IP-10 mRNA expression was rapidly induced and then declined. Our data
further indicate that induction of CCL5 expression in SMCs was mediated by IRF-1 via binding to the IRF-1 response element
in CCL5 promoter. Moreover, p38 MAPK was involved in suppression of CCL5 and IP-10 expression in SMCs through
common upstream molecule MKK3. The downstream molecule MK2 was required for p38-mediated CCL5 but not IP-10
inhibition. Our findings indicate that CCL5 induction in aorta and SMCs is mediated by IRF-1 while activation of p38 MAPK
signaling inhibits CCL5 and IP-10 expression. Methods targeting MK2 expression could be used to selectively regulate CCL5
but not IP-10 expression in SMCs.
Citation: Liu H, Ning H, Men H, Hou R, Fu M, et al. (2012) Regulation of CCL5 Expression in Smooth Muscle Cells Following Arterial Injury. PLoS ONE 7(1): e30873.
doi:10.1371/journal.pone.0030873
Editor: Paul Proost, University of Leuven, Rega Institute, Belgium
Received July 14, 2011; Accepted December 22, 2011; Published January 23, 2012
Copyright:  2012 Liu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Start-up fund to JL; National Natural Science Foundation of China (30730031) and the 973 Program (2007CB512100) to HZ. The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jliu9@slu.edu (JL); zhanghl@hebmu.edu.cn (HZ)
. These authors contributed equally to this work.
Introduction
Atherosclerosis is generally recognized a chronic inflammatory
disease characterized by arterial lesions composed of cholesterol,
immune cells and fibrosis [1,2]. Recruitment of inflammatory
immune cells as well as migration and proliferation of vascular
smooth muscle cells (VSMCs) in the wall of injured blood vessels
play critical roles in the pathogenesis of atherosclerosis [3,4].
Migration of immune cells and VSMCs to the intima is guided by
chemokines secreted from immune cells and resident vascular cells
which participate in the inflammatory process of atherosclerosis [5].
Chemokines are small soluble molecules that are best known for
their potent abilities to induce cellular migration, particularly by
leukocytes, during inflammation and infection [6,7,8]. Migration
of leukocytes to the sites of infection is a critical step for initiating a
proper immune response against invading pathogens. CCL5
(Regulated upon Activation, Normal T cell Expressed and
Secreted, RANTES) is a member of the CC chemokine family
which also includes monocyte chemoattractant protein (MCP)-1,
MCP-2, MCP-3, and macrophage inhibitory protein (MIP)-1a,
MIP-1b and I-309. CCL5 was originally discovered by subtractive
hybridization in T but not in B cells and is expressed in platelets,
macrophages, tubular epithelium, synovial fibroblasts, as well as
selected tumor cells [9]. CCL5 plays an essential role in
inflammation by recruiting T cells, macrophages, dendritic cells,
eosinophils, NK cells, mast cells, and basophils to the sites of
inflammation and infection [10,11]. It has been reported that
many chemokines, including CCL5 (RANTES) and CCL2 (MCP-
1), are increased in vascular wall cells and cooperate in leukocyte
recruitment to the injured artery during vascular remodeling [12].
Blockade of CCL5 binding to its receptor CCR5 by met-
RANTES [13] and treatment with CCL5 variant [
44AANA
47]-
RANTES [14] reduce atherosclerotic plaque formation or prevent
progression of established atherosclerotic lesions in mice. Other
studies further demonstrate that double deletion of CCR5 and
ApoE in mice reduces the development of diet-induced athero-
sclerosis [15]. Taken together, all data indicate an important role
for CCL5/CCR5 signaling pathway in the pathogenesis of
atherosclerosis.
Regulation of CCL5 in immune cells has been well studied. It
has been reported that transcription factors such as interferon
regulatory factor-3, STAT1 and NF-kB mediate CCL5 transcrip-
tion and production [16,17]. Using an Helicobacter pylori infection
model, Kudo et al showed that maximal H. pylori-induced CCL5
gene transcription required the presence of the interferon-
stimulated response element (ISRE) and the cyclic AMP-
responsive element [18]. Our previous studies further mapped
the IFN-c-inducible ISRE in the CCL5 promoter as IRF1-RE
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30873[19,20]. In SMCs Y-box binding protein-1 (YB-1) has been
reported to be able to regulate CCL5 expression in neointimal
SMCs but not in macrophages, and deletion of YB-1 in carotid
arteries inhibits CCL5 expression in SMCs and impairs neointima
formation via reduced macrophage infiltration [21]. However, it is
not fully understood how CCL5 is regulated in SMCs in response
to inflammatory signaling.
We found in this study that chemokine CCL5, IP-10 and MCP-
1 have different kinetics after balloon injury. In SMCs IFN-c
enhances LPS-induced CCL5 transcription and p38 MAPK
signaling pathway inhibits CCL5 and IP-10 transcription via
different downstream molecules.
Results
Different kinetics of chemokine expression in aorta after
balloon artery injury
To determine the expression profile of chemokines in aorta after
injury, we measured the kinetic expression of CCL5, IP-10 and
MCP-1 mRNA in aorta after balloon injury. CCL5 mRNA
expression was slightly down-regulated at day 3 and then increased
and peaked at day 7, followed by decline at day 14 after balloon
injury (Fig. 1A). In contrast, IP-10 mRNA expression was rapidly
induced and peaked at 3 days and than declined to a level similar
to uninjured aorta at day 14 after balloon injury (Fig. 1B). MCP-1
mRNA expression was also rapidly induced by balloon injury
followed by decline but kept at relatively high level at 14 days after
injury (Fig. 1C). The different kinetics of chemokine CCL5, IP-10
and MCP-1 expression after artery injury suggest that different
chemokines may play different roles in attracting different types of
host cells to the local environment to participate in generation of
local inflammation. To determine the expression levels of CCL5
receptors, we measured the expression of CCR1, CCR3 & CCR5
in aorta after balloon injury. The expression of all three CCL5
receptors (CCR1, 3 & 5) was rapidly induced at day 3 and then
declined except CCR5 (the major receptor for CCL5) which,
though gradually declined, but still remained at a relatively high
level compared to other CCL5 receptors (Fig. 1D–F), suggesting
that CCR5 may play an important role in CCL5-mediated
chronic inflammatory responses in aorta.
Vascular smooth muscle cells express chemokine CCL5,
IP-10 and MCP-1 in response to inflammatory stimuli
The increased expression of chemokine CCL5, IP-10 and
MCP-1 in aorta after balloon injury compelled us to investigate
whether vascular smooth muscle cells (VSMCs) could express
Figure 1. Kinetic expression of chemokines in aorta after balloon injury. Total RNA was extracted from aorta and used for real time
quantitative PCR (qRT-PCR) measurement of CCL5 (A), IP-1 (B) and MCP-1 (C) mRNA expression as well as CCR1 (D), CCR3 (E) and CCR5 (F) mRNA
expression. qRT-PCR data were normalized relative to GAPDH mRNA expression levels in each respective sample and further normalized to the results
from the un-treated aorta, which was set as 1. Results shown are mean plus SD of three to four independent experiments.
doi:10.1371/journal.pone.0030873.g001
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and stimulated the cells with LPS and IFN-c for different times,
with a purpose of LPS stimulation representing activation of innate
signaling TLR4, and IFN-c produced mainly from NK cells,
CD8
+ T cells and CD4
+ T helper 1 (Th1) cells representing signals
derived from host immune responses against inflammation. Rat
CCL5 mRNA expression was hardly induced by IFN-c alone
whereas strongly induced by LPS, and reached a peak at 12 hours
after LPS stimulation, and co-stimulation of rat VSMCs with LPS
and IFN-c synergistically enhanced CCL5 mRNA expression with
a peak at 24 hours (Fig. 2A), suggesting a secondary response
might be involved in CCL5 expression at the late phase.
Consistent with the in vivo data, IP-10 mRNA expression was
rapidly induced and peaked at 2–3 hrs after LPS and IFN-c
stimulation and then rapidly declined (Fig. 2B). However, in
difference from CCL5 and MCP-1, either LPS or IFN-c alone
could not induce a strong IP-10 mRNA expression (Fig. 2B). To
our surprise the expression of MCP-1 had two peaks with the early
one at 3 hours and the late one around 24 hours (Fig. 2C),
indicating the presence of primary and secondary responses of
MCP-1 expression after arterial injury. Further investigation is
desired to explore the molecular mechanisms of these different
responses of MCP-1 expression after arterial injury. Nevertheless,
these data suggest that the expression patterns of CCL5, IP-10 and
MCP-1 mRNA are similar between aorta and VSMCs.
IRF-1 mediates CCL5 mRNA expression in VSMCs
Migration of inflammatory cells to the injured sites needs
constant guidance of chemokines. Since CCL5 mRNA expression
was comparable between aorta and VSMCs and remained at a
relatively high level 7 days after injury, we focused our study on
how CCL5 expression is regulated. Next we wanted to know
whether IFN-c and LPS could induce CCL5 promoter activation
in VSMCs since steady state CCL5 mRNA expression is mainly
determined by transcription. As shown in figure 3A, IFN-c alone
had little effect on CCL5 promoter activation whereas LPS
induced more than twofold of CCL5 promoter activation
compared with untreated cells. Moreover, addition of IFN-c
dose-dependently enhanced LPS-induced CCL5 promoter activa-
tion. Since our previous studies demonstrate that IRF-1 plays an
important role in CCL5 expression in macrophages [19], we
wondered that IRF-1 may also control CCL5 expression in
VSMCs. We transiently transfected the wild type and IRF-1-
mutant CCL5 promoter into A7r5 cells and treated the cells with
IFN-c and LPS, followed by measurement of luciferase activity in
cell lysates. Consistent with the above data, IFN-c and LPS
synergistically enhanced the wild type CCL5 promoter activity
whereas the synergistic effect was almost completely lost when
IRF-1 mutant CCL5 promoter used (Fig. 3B), indicating the
importance of IRF-1 in regulation of CCL5 expression in SMCc.
Compared with empty-vector transfected cells overexpression of
IRF-1 enhanced CCL5 promoter activity in A7r5 cells transfected
with WT but not IRF-1 mutant CCL5 promoter (Fig. 3C). Taken
together, these data indicate that transcription factor IRF-1
mediates CCL5 expression via the IRF-1 response element in
CCL5 promoter in VSMCs in response to LPS and IFN-c
stimulation.
IRF-1 binds to the IRF response element in CCL5
promoter
To determine whether IRF-1 bound to CCL5 promoter, we
performed EMSA using nuclear extracts isolated from A7r5 cells
stimulated with IFN-c or LPS. As shown in figure 4A, there were
several nuclear DNA-binding complex formed with an oligonu-
cleotide containing the IRF-1 response element in CCL5
promoter, and the intensity of one binding complex was increased
upon IFN-c or IFN-c plus LPS stimulation (indicated by an
arrow). This increased binding intensity was reduced to basal level
with IRF-1 mutated probe, indicating the sequence specify of the
binding to CCL5 promoter. To further confirm IRF-1 indeed
binds to CCL5 promoter, we performed ‘‘supershift’’ EMSA using
an anti-IRF-1 antibody. The increased binding upon IFN-c plus
LPS treatment was completely supershifted by adding anti-IRF-1
antibody but not control IgG (Fig. 4B), confirming that the
increased binding complex upon IFN-c and LPS stimulation
indeed contains IRF-1.
Figure 2. Kinetic expression of chemokines in rat vascular
smooth muscle cells. Total RNA was extracted from rat smooth
vascular muscle cells treated with IFN-c, LPS, or IFN-c plus LPS for
different times as indicated and reverse transcribed into cDNA for
measurement of CCL5 (A), IP-10 (B) and MCP-1 (C) expression by qRT-
PCR. Data were normalized relative to GAPDH mRNA expression levels
in each respective sample and further normalized to the results from
the un-treated group, which was set as 1.
doi:10.1371/journal.pone.0030873.g002
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It has been reported that many cytokines, including IL-12, IL-
1b, IL-6, TNF-a and IL-10, play important roles in immune
responses and are regulated by p38 MAPK [22,23]. To investigate
whether CCL5 expression was regulated by p38 MAPK, we first
blocked p38 MAPK with SB203580 prior to IFN-c and LPS
stimulation, followed by measurement of CCL5 mRNA expres-
sion. Blockade of p38 pathway with SB203580 dose-dependently
increased CCL5 mRNA expression in A7r5 SMCs compared with
DMSO-treated cells (Fig. 5A). In line with this finding, over-
expression of p38 MAPK significantly inhibited CCL5 mRNA
expression in cells treated with IFN-c and LPS (Fig. 5B), indicating
that p38 MAPK signaling pathway suppresses CCL5 expression in
VSMCs in response to IFN-c and LPS stimulation. To dissect
which component in p38 pathway cascade was involved in inhi-
bition of CCL5 mRNA expression, we first transfected a dominant
negative mutant of MK2 (DN-MK2) or empty vector into A7r5
cells, followed by IFN-c and LPS treatment. Blocking MK2 by
DN-MK2 increased CCL5 mRNA expression (Fig. 5C), suggest-
ing that p38 acts through downstream molecule MK2 to inhibit
CCL5 expression. To further determine which upstream molecule
in p38 pathway cascade was involved in CCL5 inhibition, we
individually transfected MLK3, MKK3 and MKK6 or empty
vector into A7r5 cells followed by IFN-c and LPS stimulation. As
shown in Fig. 5D, two upstream molecules MLK3 and MKK6
enhanced IFN-c- and LPS-induced CCL5 mRNA expression
whereas MKK3 inhibited it, indicating that the upstream molecule
MKK3 and downstream molecule MK2 are participated in p38-
medited CCL5 mRNA inhibition.
p38 MAPK inhibits IP-10 expression in SMCs
To determine whether p38 MAPK was also involved in control
of IP-10 mRNA expression, we blocked p38 with SB203580 prior
to IFN-c and LPS stimulation, followed by measurement of IP-10
mRNA expression as described above. Blockade of p38 pathway
with SB203580 increased IP-10 mRNA expression in VSMCs
compared with DMSO-treated cells (Fig. 6A). Consistently,
overexpression of p38 MAPK inhibited IP-10 mRNA expression
(Fig. 6B), indicating a similar regulation of IP-10 expression as the
CCL5 by p38 signaling in VSMCs. In difference from CCL5,
blocking MK2 by dominant negative mutant DN-MK2 did not
affect CCL5 expression (Fig. 6C) and overexpression of MKK3
but not MLK3 and MKK6 inhibited IP-10 mRNA expression
(Fig. 6D), suggesting that MKK3 but not MK2 is involved in p38-
mediated IP-10 inhibition in VSMCs.
Discussion
Chronic inflammation plays an important role in the patho-
genesis of atherosclerosis. One of the critical steps for initiation of
inflammation is recruitment of immune cells such as T cells, NK
cells and monocytes to atherosclerotic lesions under the guidance
of chemokines. High levels of chemokines secreted around
vascular cells within the lesions determine which types of cells
could migrate to the lesion. Our data indicate that multiple
chemokines were induced in aorta after balloon artery injury
(Fig. 1). Interestingly, chemokine CCL5 and IP-10 showed a
different kinetics in aorta following injury in that IP-10 was fast
induced and reached a peak at day 3 whereas CCL5 was induced
Figure 3. IRF-1 mediates CCL5 transcription in smooth muscle cells. (A) 5 mg of CCL5 promoter driven luciferase construct was transfected
into A7r5 cells by Lipofectamin2000. The transfected cells were treated with different amounts of IFN-c as indicated, LPS (1 mg/ml), or IFN-c plus LPS
for 7 hours, followed by cell lysis and detection of luciferase activity. (B) 5 mg of WT and IRF-1 mutant CCL5 promoter constructs were respectively
transfected into A7r5 cells by Lipofectamine2000 and treated with IFN-c (10 ng/ml) and LPS (1 mg/ml) for 7 hrs, followed by measurement of
luciferase activity in cell lysates. Luciferase activities were normalized to the activities obtained in WT CCL5 promoter transfected cells without
treatment which was set as 1. (C) 5 mg of WT and IRF-1 mutant CCL5 promoter constructs were respectively co-transfected with PACT-c (empty
vector) and IRF-1 expression plasmid into A7r5 cells by Lipofectamine2000, followed by IFN-c and LPS treatment. Luciferase activity was measured in
cell lysates. All results shown represent mean plus SD of three to four separate experiments.
doi:10.1371/journal.pone.0030873.g003
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kinetics suggests that during inflammation each chemokine may
participate in directing specific type of cells to migrate to
atherosclerotic lesions. It has been reported that MCP-1 mediates
transendothelial migration but not shear-resistant arrest of
monocytes on activated endothelial cells [24] and IP-10 has been
described as a chemoattractant for monocytes and activated
lymphocytes [25]. The association of CCL5 induction with
leukocyte recruitment in the injured arteries has been recently
demonstrated by Boehm’s group. Using CCL5 knockout mice they
have demonstrated that local induction of CCL5 in medial
VSMCs regulates CD3
+ T cell and macrophage infiltration and
late neointimal formation [26]. We did not measure serum CCL5
levels in this study because the connection between serum CCL5
levels and the presence of coronary heart disease is controversial
[27,28]. Moreover, local CCL5 expression has been shown to
closely associate with chronic inflammation in atherosclerosis [26].
Platelet-derived CCL5 deposits on endothelial cells to induce
monocyte arrest and promote atheroscrosis [29,30], further
indicates the role for local CCL5 in facilitation of local
inflammation. It will be interested to investigate the correlation
of serum CCL5 levels to the degrees of local arterial inflammation
in future study.
Interferons, including type I and type II IFNs, are cytokines that
effectively enhance host defenses against various infections and
immunosurveillance against tumors [31]. IFN-c, the only member
of the type II IFN family, is produced by a variety of cell types,
including NK cells, NK T cells, CD4
+ and CD8
+ T cells as well as
SMCs. IFN-c is essential for mounting both innate and cellular
immune responses. It also plays an important role in the chronic
nature of inflammatory responses associated with atopic derma-
titis, rheumatoid arthritis, and systemic lupus erythematosus [31].
IFN-c acts on a remarkable range of distinct cell populations
including macrophages, natural killer cells, B cells, ECs and
VSMCs. It has been shown that IFN-c is necessary and sufficient
to cause vascular remodeling in a mouse model of atheroma, as the
serological neutralization or genetic absence of IFN-c markedly
reduces the extent of atherosclerosis [32]. IFN-c is thought to
participate in promoting atherogenic responses through transcrip-
tion factor STAT1, which plays a major role in driving the pro-
inflammatory responses leading to EC dysfunction, VSMC
proliferation and vascular damage [33]. Our data suggest that
IFN-c can promote local inflammatory responses through
induction of CCL5 via IRF-1 in VSMCs.
TLR4 is the first toll-like receptor (TLR) being discovered in the
TLR family. TLR4 is expressed on a variety of cells, including ECs
and VSMCs, and thus initiates and sustains the inflammatory
response in atherosclerosis [34]. TLR4 signaling leads to the
induction of various target genes, including type I IFNs, pro-
inflammatory cytokines, chemokines and cell surface molecules
Figure 4. IRF-1 specifically binds to the CCL5 promoter. (A) Nuclear extracts were isolated from A7r5 cells following IFN-c or LPS stimulation
for 4 h. EMSA was performed with 10 mg of nuclear extract for each sample and a double-stranded oligonucleotide probe containing the 2161/2134
region of the CCL5 promoter (sequence given with the critical IRF-RE underlined). (B) ‘‘Supershift’’ EMSA was performed with the 2161/2134 probe
and nuclear extracts from IFNc/LPS-stimulated macrophages with an anti IRF-1 antibody and its control rabbit IgG being used. The IRF-1-related
complex is indicated by an arrow.
doi:10.1371/journal.pone.0030873.g004
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remodeling, such as atherosclerotic lesions, endogenous ligands
for TLR4, including HSP, OxLDL and HMGB1, etc, are
accumulated in the local environment that play a direct role in
promoting inflammation [37]. Using LPS and IFN-c to mimic the
endogenous innate and adaptive immune signals, we found that in
difference from IP-10 which requires both IFN-c and LPS
signaling for a strong induction in rat SMCs (Fig. 2B), CCL5
could be induced by LPS alone and further increased by addition
of IFN-c at a later time point (Fig. 2A), whereas MCP-1 could be
induced by either IFN-c or LPS signaling (Fig. 2C). The
expression pattern of IP-10 is different from a previous report
that IP-10 is gradually induced till day 14 in rat carotid artery
following balloon angioplasty [38]. We reason that this difference
might be due to different procedures of angioplasty or different
methods for detection of mRNA expression.
IFN-c dose-dependently increased CCL5 promoter activation
in VSMCs treated with LPS (Fig. 3). Our data further
demonstrated that like in macrophages transcription factor IRF-
1 mediates CCL5 transcription via the IRF-1 binding site in CCL5
promoter (Figs. 3 & 4). The IRF family consists of nine
transcription factors that commonly possess a unique helix-turn-
helix DNA-binding motif at the N-terminus and an activation
domain in the C-terminus [39]. IRF-1, the first member of the
IRF family to be identified, targets different sets of genes in various
cell types in response to diverse cellular stimuli and evokes
appropriate innate and adaptive immune responses [39]. Our
previous studies demonstrated that IFN-c-induced IRF-1 differ-
entially regulates IL-12 p35 and p40 gene expression in
macrophages [40]. IRF-1 has been well established as a critical
effector molecule in IFN-c-mediated signaling and in the
development and function of NK cells, NK T cells and cytotoxic
T lymphocytes [41,42,43,44,45,46]. In this study our data indicate
that IRF-1 also plays an important role in induction of CCL5
expression in VSMCs.
MAPK signaling pathway is involved in regulation of many
cytokine and chemokine expression during inflammation. Since
VSMCs are different from macrophages in CCL5 expression, in
that the maximal CCL5 expression in VSMCs requires both IFN
and LPS signaling whereas in macrophages LPS alone is sufficient,
we decided to investigate the effects of MAPK on CCL5
expression in response to LPS and IFN-c stimulation. Both
blocking and overexpression data indicate that p38 MAPK
triggered by LPS and IFN-c inhibited CCL5 (Fig. 5) and IP-10
(Fig. 6) expression in VSMCs. When we looked more details to
which molecule in the cascade actually was involved in signaling
transduction, it turned out that MK2 mediated inhibition of CCL5
(Fig. 5C) but not IL-10 (Fig. 6C) in VSMCs in response to LPS
Figure 5. The role of p38 MAPK in CCL5 expression. (A) 1610
6 A7r5 cells were treated with different amounts of a p38 MAPK antagonist
SB203580 for 1 h prior to addition of various stimuli as indicated. An identical amount of dissolvent DMSO was used for negative controls. 6 hrs later,
total RNA was extracted for measurement of CCL5 mRNA expression by qRT-PCR. 5 mg of different expression plasmids encoding different molecules
involved in the p38 MAPK signaling pathway including p38a (B), and DN-MK2 (C), as well as MLK3, MKK3, and MKK6 (D) or empty vector were
transiently transfected with Lipofectamine2000. 48 h after transfection, the cells were treated with LPS (1 mg/ml) plus IFN-c (10 ng/ml) for 6 h,
followed by measurement of CCL5 mRNA expression by qRT-PCR. qRT-PCR data were normalized relative to GAPDH mRNA expression levels in each
respective sample and further normalized to the results from the un-treated group, which was set as 1. Results shown are mean plus SD of three
independent experiments.
doi:10.1371/journal.pone.0030873.g005
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mediated both inhibition (Figs. 5D & 6D). These data suggest that
methods targeting MK2 expression could be used to selectively
regulate CCL5 but not IP-10 expression in SMCs, which may
have potential therapeutic effects on preventing chronic inflam-
mation in the blood vessel.
Materials and Methods
Rat carotid artery balloon injury
All procedures were in accordance with institutional guidelines
approved by the Animal Care and Ethical Committee of Hebei
Medical University (Shijiazhuang, China) under policies adhering
to IASP guidelines for use of animals (the approval ID is 000172).
Male Sprague-Dawley rats weighing 350 to 400 g were anesthe-
tized with ketamine (40 mg/kg) and xylazine (5 mg/kg). The left
common carotid artery was denuded of endothelium and stretched
by three passages of a 2F embolectomy catheter according to
standard protocols [47,48]. At 3, 7, and 14 days after injury,
animals were euthanized; both right (uninjured control) and left
(injured) carotid arteries were harvested and snap-frozen in liquid
nitrogen for RNA extraction.
Cells
Arterial smooth muscle cells were harvested from the aortas of
male Sprague-Dawley rats (200 to 250 g, Charles River
Laboratories) by enzymatic dissociation [48,49] The cells were
cultured in DMEM supplemented with 10% FCS (Sigma, St.
Louis, MO, endotoxin NMT 10.0 EU/ml), 100 U/mL penicillin,
100 mg/mL streptomycin, and 10 mmol/L HEPES (pH 7.4)
(Sigma Chemical Co). Rat vascular smooth muscle cells (VSMCs)
were passaged every 3 to 5 days, and experiments were
performed on cells four to six passages from primary culture.
The rat aortic smooth muscle cell line (A7r5 cells) was obtained
from American Type Culture Collection, and maintained in
DMEM supplemented with 2 mM glutamine, 100 units/ml of
penicillin and streptomycin and 10% FBS (Sigma, St. Louis, MO,
endotoxin NMT 10.0 EU/ml).
Plasmids
Mouse CCL5 promoter-driven luciferase plasmids were gener-
ated previously [19]. Expression vectors pAct-1 (IRF-1), and
control pAct-C were originally provided by Dr. T. Taniguchi
(University of Tokyo, Japan). MAPK expression plasmids
encoding MLK3, MKK3, MKK6, p38, dominant negative
mutant MK2 and p38a were provided by Dr. Aihao Ding (Weill
Cornell Medical College). All plasmid DNA were prepared with
QIAGEN Endo-free Maxi-Prep kits.
Reagents
LPS from Escherichia coli 0217:B8 were purchased from Sigma-
Aldrich (St. Louis, MO). Recombinant mouse IFN-c was
purchased from Genzyme (Boston, MA). p38 MAPK antagonist
SB203580 was purchased from Calbiochem (San Diego, CA).
Figure 6. The role of p38 MAPK in IP-10 expression. (A) 1610
6 A7r5 cells were treated with different amounts of a p38 MAPK antagonist
SB203580 for 1 h prior to addition of various stimuli as indicated. An identical amount of dissolvent DMSO was used for negative controls. 6 hrs later,
total RNA was extracted for measurement of IP-10 mRNA expression by qRT-PCR. 5 mg of different expression plasmids encoding different molecules
involved in the p38 MAPK signaling pathway including p38a (B), and DN-MK2 (C), as well as MLK3, MKK3, and MKK6 (D) or empty vector were
transiently transfected with Lipofectamine. 48 h after transfection, the cells were treated with LPS (1 mg/ml) plus IFN-c (10 ng/ml) for 6 h, followed by
measurement of IP-10 mRNA expression by qRT-PCR. qRT-PCR data were normalized relative to GAPDH mRNA expression levels in each respective
sample and further normalized to the results from the un-treated group, which was set as 1. Results shown are mean plus SD of three independent
experiments.
doi:10.1371/journal.pone.0030873.g006
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Reverse-transcription reactions were carried out as previously
described [50], Quantitative real time PCR (qRT-PCR) was
performed by a modified protocol. Briefly, cDNA samples
converted from 1 mg of total RNA were diluted and studied at
several concentrations. Diluted cDNA was mixed with a pair of
primers (10 mM) targeting rat CCL5, IP-10, MCP-1 or GAPDH
cDNA sequences, with SYBR green PCR master mix (Sigma-
Aldrich, St. Louis) in a 15 ml volume. The following primers were
used for PCR amplification of the rat CCL5 cDNA: sense:
gcagctgcatccctcaccgt, antisense: gcagcagggagtggtgtccg; rat IP-10
cDNA: sense: cgccacagtgctgagaccga, antisense: caccctgtagtgggag-
tagcagct; rat MCP-1 cDNA sense; tgtcacgcttctgggcctgt, antisense:
agcagcaggtgagtggggca; and rat GAPDH cDNA: sense: gacatg
ccgcctggagaaac; antisense: agcccaggatgccctttagt.
Transfection assay
Transient transfections were performed according to manufac-
ture’s protocol (Invitrogen). Briefly, for each condition 3610
6
A7r5 cells were transiently transfected with 4 mg of DNA plasmids
(including reporter, effector, internal control and carrier DNA) by
Lipofectamin2000. The transfected cells were cultured in
RPMI1640 complete medium containing 10% FBS and incubated
for 48 h prior to performing experiments. To measure luciferase
activity, cells were pelleted and resuspended in lysis buffer.
Luciferase activity was measured in cell lysates.
Nuclear extract preparation
Nuclear extracts for EMSA were prepared according to the
methods of Schreiber et al. [51]. Briefly, 5610
7 A7r5 cells were
washed and resuspended in 400 ml buffer containing 10 mM
HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 1 mM DTT,
0.5 mM PMSF for 15 min on ice. Cells were lysed in 0.6% NP-40
with inversion for 10 sec. The homogenate was centrifuged for
5 min and the nuclear pellet was resuspended in ice-cold buffer
containing 20 mM HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA,
1 mM DTT, 1 mM PMSF at 4uC for 30 min with rotating.
Following centrifugation for 10 min, the supernatant was either
used immediately or frozen at 270uC.
LightShift Chemiluminescent EMSA
LightShift Chemiluminescent EMSA was performed according
to the manufacture’s protocol (Pierce, Rockford, IL). Briefly, single
strand wild type and IRF-1 mutant oligonucleotides were labeled
with biotin using a Biotin 39 End DNA Labeling Kit (Pierce,
Rockford, IL). Equal amounts of labeled and complementary
oligos were annealed to prepare double-strand wild type and
mutant probes by heating at 90uC for 2 min, followed by slowly
cooling to room temperature for 30 min. The labeled double-
strand probes were mixed with 10 mg crude nuclear extracts and
incubated at room temperature for 20–30 min in the presence of
1 mg poly(dI-dC). The mixture was then fractionated through a
5% native polyacrylamide gel in 0.56TBE buffer for about 1 h at
100 V. The gel was transferred to positively charged nylon
membrane at 4uC for 1 h at 100 V. When transfer was completed,
the membrane was cross-linked at 120 mJ/cm
2 using a commer-
cial UV-light cross-linker instrument equipped with 254 nm bulbs.
Then, the membrane was blocked and applied with Streptavidin-
Horseradish Peroxidase Conjugate (1:300 dilution) for 15 min,
followed by thoroughly washing, and exposed to X-ray film after
incubation with the chemiluminescence reagents. The X-ray film
was developed according to the manufacture’s instruction.
Statistical analysis
Student t test was performed wherever applicable. Standard
deviation of the mean is shown unless otherwise indicated.
*, p,0.05; **, p,0.01; ***, p,0.001.
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